Efficacy and safety of pegylated interferon Alfa-2a or Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: A systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 56, Issue 7, 2013, Pages 961-967

  Druyts, Eric ^a   Thorlund, Kristian ^b   Wu, Ping ^a   Kanters, Steve ^a   Yaya, Sanni ^a   Cooper, Curtis L ^c   Mills, Edward J ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Children; Hepatitis C; Meta analysis; Peg interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ALOPECIA; ANEMIA; ANTIVIRAL THERAPY; CHILDHOOD DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY VIROLOGIC RESPONSE; GENOTYPE; GROWTH INHIBITION; HEPATITIS C; HUMAN; INJECTION SITE ERYTHEMA; LEUKOPENIA; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84875043423     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1031     Document Type: Review

References (39)

1. Druyts E, Mills E, Nachega J, O'Regan C, Cooper C. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012; 5: 11-21.
2. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alpha-2b in chronic hepatitis c: systematic review of randomized trials. Hepatology 2010; 51: 1176-84.
3. Alavian S, Behnava B, Tabatabaei S. The comparative efficacy and safety of peginterferon alpha-2a vs 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon 2010; 10: 121-31.
4. Singal A, Jampana S, Anand B. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci 2011; 56: 2221-26.
5. Wirth S, Kelly D, Sokal E, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2011; 52: 233-37.
6. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18: 99-104.
7. Ghany M, Strader D, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
8. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-58 e1.
9. Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis C in children: a systematic review. PLoS One 2010; 5:e11542.
10. Indolfi G, Bartolini E, Casavola D, Resti M. Chronic hepatitis C virus infection in children and adolescents: epidemiology, natural history, and assessment of the safety and efficacy of combination therapy. Adolesc Health Med Ther 2010; 1: 115-28.
11. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
12. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-8.
13. Zhang H, Yang X, Zhu S, et al. An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C [in Chinese]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2005; 19: 185-7.
14. Jara P, Hierro L, de la Vega A, et al. Efficacy and safety of peginterferon- alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142-8.
15. Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9: 156-60.
16. Pawlowska M, Pilarczyk M, Halota W. Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16:CR616-21.
17. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-31.
18. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-7.
19. Kowala-Piaskowska A, Figlerowicz M, Mozer-Lisewska I, Sluzewski W. Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C [in Polish]. Przegl Epidemiol 2005; 59: 491-98.
20. Kowala-Piaskowska A, Sluzewski W, Figlerowicz M, Mozer-Lisewska I. Factors influencing early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepatol Res 2005; 32: 224-6.
21. Pawlowska M, Palewicz E, Halota W. Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C [in Polish]. Przegl Epidemiol 2006; 60: 71-7.
22. Rumbo C, Fawaz RL, Emre SH, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006; 43: 209-16.
23. Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006; 43: 499-505.
24. Baker RD, Dee D, Baker SS. Response to pegylated interferon alpha- 2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 2007; 41: 111-4.
25. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Sluzewski W. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol Drug Saf 2007; 16: 1095-103.
26. Kowala-Piaskowska A, Sluzewski W, Figlerowicz M, Mozer-Lisewska I. Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. Infection 2007; 35: 175-9.
27. Inui A, Komatsu H, Sogo T, Hashimoto T, Fujisawa T. Pegylated interferon- alpha2b and ribavirin combination therapy for pediatric patients with chronic hepatitis C. Acta Hepatologica Japonica 2008; 49: 386-88.
28. Kups J, Wozniakowska-Gesicka T. Peginterferon alpha-2b for the treatment of chronic hepatitis C in children [in Polish]. Przegl Pediatr 2008; 38: 101-6.
29. Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 2009; 76: 895-8.
30. Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-7.
31. Tajiri H, Inui A, Kiyohara Y, et al. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 2009; 21: 1256-60.
32. Sood A, Sobti P, Midha V, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010; 29: 62-5.
33. Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON. Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study. J Pharm Pract 2011; 24: 203-10.
34. Bortolotti F, Indolfi G, Zancan L, et al. Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades. Dig Liver Dis 2011; 43: 325-9.
35. Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological adverse events and sustained viral response in children undergoing therapy for chronic hepatitis C infection. Hepat Mon 2011; 11: 968-74.
36. Rodrigue JR, Balistreri W, Haber B, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology 2011; 53: 1468-75.
37. Sluzewski W, Kowala-Piaskowska A, Wysocki J, et al. Treatment of chronic hepatitis C in children with pegylated interferon alpha2a and ribavirin - a multi-center study. Acta Pol Pharm 2012; 69: 319-26.
38. Velmishi V, Dervishi E, Cullufi P, Bali D, Durro V. Treatment and follow up of children with chronic hepatitis C in Albania. Virol J 2012; 9: 17.
39. Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the Pediatric Study of Hepatitis C (PEDS-C) trial. Hepatology 2012; 56: 523-31.